TQB 3912
Alternative Names: TQB-3912Latest Information Update: 03 Oct 2023
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 24 Aug 2023 TQB 3912 is available for licensing in World as of 24 Aug 2023. https://www.cttq.com/en/
- 24 Aug 2023 Preclinical trials in Solid tumours in China (PO) before August 2023
- 24 Aug 2023 Chia Tai Tianqing Pharmaceutical Group plans a phase I trial for Solid tumours (Late stage disease) in China (PO, Tablet) in August 2023 (NCT05997342)